Why Valeant Stock Continues To Fall

  • Valeant’s business model of buying drugs and hiking prices succeeded.
  • Its use of specialty pharmacies may have been skirting the law.
  • There may be no bottom in this stock.

Valeant Pharmaceuticals (NYSE:VRX) would appear to have the perfect business model. Buy drug companies, fire the researchers, hike the prices and take the profits to Canada. Wash, rise, repeat.

But competition could be a problem. Hike prices and doctors might recommend another drug, even a generic. Valeant’s solution was allegedly to work with specialty pharmacies devoted to making certain that the name brand would be dispensed, even if it was more expensive, and even if the doctor didn’t really care.

The risk is that prosecutors may call that fraud, especially if it’s not an arms-length relationship. Medco Containment was able to get away with massive fines as it was purchased by Express Scripts Holding (NASDAQ:ESRX). Will Valeant?

The reporter selling the story that they may not is a “short” researcher, Citron Research, a company that writes reports designed to take stocks down and profit from it. Their report was followed by an anonymous file detailing the Valeant relationship with former Medco executive Laizer Kornwasser, accusing him of setting up specialty pharmacy Philidor RX, and affiliates, on behalf of a Valeant unit called KGA Fulfillment Services.

Since the Citron piece came out, Valeantstock has lost over half its value. More important, the company was subpoenaed by U.S. prosecutors and the U.S. Senate has begun investigating the company’s business practices. CEO Michael Pearson was forced to liquidate 1.3 million shares to satisfy a margin call. Valeant stock has plunged dramatically in last three months.
VRX stock chart

Source:Valeant Stock Price Data by amigobulls.com

A conference call by Valeant tried to wave the problem away by saying they had an option to buy Philidor, but Citron called this a cover-up of phantom accounts. Bill Ackman of Pershing Square, a hedge fund owner and major Valeant stockholder, moved to support the stock by buying more shares, as did Martin Shkreli, who engages in a similar business model at Turing Pharmaceuticals. As the stock fell analysts continued to support Valeant and called it a bargain.

Even at its present level, however, Valeant is selling at a Price/Earnings multiple of over 40. That’s higher than Alphabet Inc-C (NASDAQ:GOOG). Would you really rather own Valeant than Google?

By focusing on short-term profits, price hikes, manipulation of the payment system and overseas moves since the Affordable Care Act passed in 2010, all drug companies have made themselves vulnerable to re-regulation. The political and regulatory environment has shifted, even since 2013. The desire by prosecutors for “perp walks,” executives being paraded into courthouses wearing handcuffs, has increased dramatically.


My view on the drug stocks remains that they’re vulnerable to competition from biosimilars and other forms of competition. It’s a bearish call not based at all on possible illegality. But with that risk factor now introduced, I don’t see a bottom in companies like Valeant.

Dana Blankenhorn Dana Blankenhorn   on Amigobulls :
Author's Disclosures & Disclaimers:
  • I do not hold any positions in the stocks mentioned in this post and don't intend to initiate a position in the next 72 hours
  • I am not an investment advisor, and my opinion should not be treated as investment advice.
  • I am not being compensated for this post (except possibly by Amigobulls).
  • I do not have any business relationship with the companies mentioned in this post.
  • See Amigobulls' policy on anonymous authors who use a pseudonym
Amigobulls Disclosures & Disclaimers:

This post has been submitted by an independent external contributor. This author may or may not hold any positions in the stocks discussed. Neither Amigobulls, nor any members of its staff hold positions in any of the stocks discussed in this post. Amigobulls has not verified the author’s positions in the stocks discussed, and does not provide any guarantees in this regard. The author may be paid by Amigobulls for this contribution, under the paid contributors program. However, Amigobulls does not guarantee the authenticity or accuracy of the information provided by the author in this post.

The author may not be a qualified investment advisor. The opinions stated in the post should not be treated as investment advice. Buying and selling of securities carries the risk of monetary losses. Readers/Viewers are advised to carry out their own due diligence and consult their investment advisors before making any investment decisions.

Amigobulls does not have any business relationship with any of the companies covered in this post. This post represents the views of the author/contributor and may not reflect the views of Amigobulls.

At Amigobulls, we prefer that our authors disclose their real names. However, due to a variety of reasons, author's may prefer otherwise. Recognizing the fact that the ideas conveyed carry greater significance, and to facilitate the dissemination of these ideas, we allow authors to use a pseudonym. However, we do collect the same of details from anonymous authors, as we do from others, like the author's real name and contact information. Of course, this information remains confidential with us, and is not displayed on the site.
Further, to protect the interests of our readers/viewers, anonymous authors are required to make the same set of disclosures as other authors. For more details, you can write to any of our in-house editors at contributions@amigobulls.com.

show more

Comments on this article and VRX stock

Do share this awesome post